Déjà Vu: Revived Mifepristone Case Puts FDA And Pharma At Risk Again

Three US states are attempting to intervene in a lawsuit that seeks to roll back changes the Food and Drug Administration made to the abortion pill mifepristone’s Risk Evaluation and Mitigation Strategy, a move that puts the entire agency’s drug approval process – and the pharmaceutical industry that relies upon the certainty of the status quo – in jeopardy, again.